Navigation Links
Yongye Biotechnology International, Inc. Appoints New Independent Auditor
Date:7/10/2008

he meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. All such forward-looking statements involve risks and uncertainties, including, but not limited to: statements regarding the Company's products; marketing and sales; patents and regulatory approvals; the effect of competition and proprietary rights of third parties; the need for and availability of additional financing and access to capital; the seeking of joint development, licensing or distribution and collaboration and marketing arrangements with other companies. There can be no assurance that such forward-looking statements will prove to be accurate and Yongye undertakes no obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements.

For more information, please contact:

Yongye Biotechnology International, Inc.

Larry Gilmore

Vice President of Corporate Strategy

Tel: +86-10-8232-8866 x8880

Fax: +86-10-8231-1797

Email: larry.gilmore@gmail.com


'/>"/>
SOURCE Yongye Biotechnology International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
2. Genetic Engineering & Biotechnology News reports on novel hit-to-lead drug discovery
3. Dietitian Mary Lee Chin Comments on Proven Value and Safety of Food Biotechnology in New Online Video
4. N.C. Biotechnology Center Launches Industrial Fellowship Program
5. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
6. In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study
7. Pharsight to Present on Literature-Based Disease Modeling Approaches at AAPS National Biotechnology Conference
8. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
9. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
10. Gen-Probe to Webcast Presentation at Seventh Annual Needham Biotechnology and Medical Technology Conference
11. Inverness Medical Innovations to Present at 7th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference on June 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Calif. , July 1, 2015   ... on the development of groundbreaking drugs to treat ... announced today that Robert G. Miller , ... at Sutter Health,s California Pacific Medical Center in San ... ALS Association for $1.5 million to help fund ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Apex Therapeutics ... BIO International Convention in Philadelphia, PA. , The presentation took place on ... outlined the plans for the development of APX3330 for the treatment of pancreatic cancer. ...
(Date:6/30/2015)... - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that ... approved the resolutions relating to: (i) a private ... at a price of $2.67 per unit (the ... one common share and 0.075358 common share purchase ... and (ii) the amendment to Resverlogix,s articles to ...
(Date:6/30/2015)... ... 30, 2015 , ... uBiome and OpenBiome Partner for Microbiome ... fecal microbiota transplantation in C. difficile patients. , SAN FRANCISCO, uBiome and OpenBiome ... microbiota transplantation (FMT) as a treatment for Clostridium difficile infections (C. diff). , ...
Breaking Biology Technology:Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3
... 24 United Therapeutics Corporation (Nasdaq: UTHR ... first quarter financial results before market open on Friday, ... on Friday, May 1, 2009, at 9:00 a.m. Eastern ... with international callers dialing 719-325-4795. A rebroadcast of ...
... plays a key role in determining risk for colorectal ... the United States. Several common genetic markers have ... finding the biological events that lead to cancer can ... online in Genome Research (www.genome.org), scientists have ...
... ULURU Inc. (NYSE Amex: ULU ) ... wounds using Altrazeal(TM) along with pre-clinical and physical data on ... Society for Advance Wound Care Conference ("SAWC") being held in ... data will be presented on posters on display during the ...
Cached Biology Technology:Beyond associations: Colorectal cancer culprit found 2ULURU to Present Clinical Evidence and Advanced Research on Altrazeal at the Society for Advance Wound Care Conference for 2009 2
(Date:6/23/2015)... Fla. , June 23, 2015 /PRNewswire/ ... management and authentication solutions, today announced enhanced functionality ... multi-factor authentication solution.  The enhancements build on ... of the DigitalPersona Altus platform and provide ... compatibility. In today,s environment of ...
(Date:6/18/2015)... , June 18, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces that its ... segment on "Money on the Mark", scheduled to air on ... June 20 th . The broadcast ... from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO Gino ...
(Date:6/17/2015)... Germany , June 17, 2015 ... Standard: QIA) today launched new Investigator ® STR assay ... the United States . The new genetic ... key genomic markers (short tandem repeats or STRs) for DNA ... evaluate the quality of DNA in each sample, a novel ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... (Cincinnati, OH) In a study published today in the ... an international team of researchers based in the U.S. and ... lethal, breath holding episodes associated with the neurological disease Rett ... that affects around 1 in 10,000 young girls. On October ...
... Institute in Boston have identified a new type of cell ... animal,s own cells from immune system attack. This ... drive lupus and other autoimmune diseases in which the immune ... The discovery, published in the September 16 issue of ...
... October 4, 2010 Onconova Therapeutics, Inc. announced ... regarding a Special Protocol Assessment (SPA) for the design ... 01910.Na) as monotherapy in patients with myelodysplastic syndromes (MDS), ... the bone marrow. The SPA provides FDA evaluation and ...
Cached Biology News:Research breakthrough hailed on the anniversary of gene discovery 2Discovery of a cell that suppresses the immune system 2Onconova announces FDA agreement of a SPA for a pivotal phase 3 trial of Estybon in MDS 2